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In this study, we investigated the presence of Epstein–Barr virus (EBV) in liver tissue from 35 patients with hepatocellular
carcinoma (HCC). EBV DNA was detected in 13 patients (37%) by Southern blot hybridization. In 10 of these patients, EBV DNA
was present in tumor tissue only, whereas in the other 3, it was detected in both tumor and nontumor tissues. The quantity
of EBV DNA detected was equivalent to 1–10 viral DNA molecules/100 cells. EBV-determined nuclear antigen was detected
in 7–13% of the carcinoma cells in three tumor tissue samples that contained approximately one copy of the EBV genome/10
cells. A single terminal fragment of EBV DNA was identified in these tissues, suggesting that the EBV-infected cells in HCC
represent clonal proliferation. Western blotting and reverse transcription–polymerase chain reaction analyses demonstrated
that these three tumor tissue specimens were positive for EBV-determined nuclear antigen 1 and BamHI A transcripts but
were negative for the other latent EBV products, including EBV-encoded small RNA. The results indicated that there is a high
EBV load in HCC tissue and that all of the HCC tissue examined showed a novel pattern of EBV latency characterized by
absence of EBV-encoded small RNA expression. © 1999 Academic Press
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Epstein–Barr virus (EBV) is a human herpesvirus that
nfects the majority of the human population. EBV is
ommonly transmitted by saliva and establishes latent
nfection in B lymphocytes, where it persists for the
ifetime of the host. The virus has been associated with
uman malignancies, such as Burkitt’s lymphoma, naso-
haryngeal carcinoma, opportunistic lymphoma in immu-
ocompromised hosts, and some cases of Hodgkin’s
isease, which can occur after prolonged persistence
nd reactivation of latent EBV (Rickinson and Kieff, 1996).
BV persists in a latent form in such tumor cells, and
hree distinct forms of EBV latent gene expression have
een described (Kerr et al., 1992). B lymphoblastoid cell
ines (LCL) transformed by EBV in vitro display the full
attern of latent gene expression (latency III) encom-
assing six nuclear antigens [EBNAs 1, 2, 3A, 3B, 3C, and
eader protein (Lp)], three latent membrane proteins
LMPs 1, 2A, and 2B), transcripts from the BamHI-A re-
ion of the virus genome (BARF0), and EBV-encoded
uclear RNAs (EBER1 and EBER2). This pattern is seen
n opportunistic lymphoma cells. EBV-positive Burkitt’s
ymphoma cells express EBNA1 but not other EBNAs
nd LMPs (latency I). Latency II is characterized by
1 To whom reprint requests should be addressed. Fax: 81-11-717-
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196xpression of EBNA1 and all the LMPs and is recognized
n non-B cell tumors, such as nasopharyngeal carci-
oma, T cell tumors, and Hodgkin’s disease. BARF0 and
BERs are commonly expressed in all latent forms men-
ioned above.
The EBER sequence is usually detectable in the nu-
leus of latently EBV-infected cells. Its high levels of
xpression (up to 107 copies/cell) facilitate detection by
n situ hybridization (ISH) (Chang et al., 1992; Howe and
hu, 1989). The absence of EBER expression has been
escribed previously in the case of lytic EBV infection
Gilligan et al., 1990) but not of latent infection. EBER ISH
as served as something of a diagnostic gold standard
f EBV existence in tissue samples.
This study was aimed to clarify the association of
BV with hepatocellular carcinoma (HCC). The impor-
ance of hepatitis B virus (HBV) and hepatitis C virus
HCV) infection in the development of primary HCC
as been established in epidemiological studies (Bea-
ley et al., 1981; Kiyosawa et al., 1990; Obayashi et al.,
972; Resnick et al., 1983). However, evidence for a
irect role of hepatitis viruses in liver carcinogenesis
emains tentative. Carcinogenesis is a multistep pro-
ess, and although these viruses are likely to be
ssential contributing factors, alone they are insuffi-
ient for hepatocarcinogenesis. EBV can be associ-
ted with liver disease during EBV-induced infectious
ononucleosis and post-transplantation lymphoprolif-
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197EBV LATENCY IN HEPATOCELLULAR CARCINOMArative disorders (Rickinson and Kieff, 1996). We there-
ore addressed whether EBV infection may be a co-
actor for hepatocarcinogenesis. The results indicated
hat there was a high EBV load in HCC tissue and that
ll of the HCC tissue examined showed a novel pattern
f EBV latency characterized by absence of EBER
xpression.
RESULTS
etection of EBV DNA by Southern blot hybridization
EBV DNA was detected in 13 (37%) of the 35 patients
ith HCC. The virus was present in only the tumor
issues from 10 patients and in both tumor and nontumor
issues from 3 patients (Fig. 1). The assay could detect a
ingle copy of EBV DNA/100 cells. Tumor tissues from six
atients (patients 12, 17, 21, 30, 32, and 34) contained
bout one copy of EBV DNA/10 cells. In comparison with
erum HBV and HCV markers, EBV DNA was detected in
of the 22 HCV-positive HCCs (patients 2–23), 1 of 8
BV-positive HCCs (patients 24–31), and 2 of 4 hepatitis
irus-negative HCCs (patients 32–35). Patient 1, who was
ositive for HBV and HCV, was also positive for EBV
NA. All control samples from normal liver tissues were
FIG. 1. Southern blot hybridization of EBV DNA in HCC tissues. The
umber on each lane indicates the patient from whom the DNA was
xtracted (N, nontumor tissue; T, HCC tumor tissue). The patients were
tratified according to their hepatitis status: patient 1, both hepatitis B
ntigen (HBVAg) and hepatitis C antibody (HCVAb) positive; patients
–23, HCVAb positive only; patients 24–31, HBVAg positive only; pa-
ients 32–35, hepatitis virus negative. P1, 42 ng of Raji cell DNA,
orresponding to one EBV copy/10 cells; P2, 4.2 ng of Raji cell DNA,
orresponding to one EBV copy/100 cells; NC, 20 mg of BJAB cell DNA.
-DNA digested with HindIII was used as the size marker and is
ndicated on the left (in kb pairs).egative for EBV DNA.dentification of EBV-infected cells by
mmunofluorescence
To localize the EBV-infected cells, three tumor tissue
pecimens (from patients 12, 21, and 30) that contained
bout one copy of EBV DNA/10 cells and were available
s frozen tissues, were examined by immunofluores-
ence using multiple EBNA-positive and -negative hu-
an sera. Clinical details of the three patients are shown
n Table 1. EBNA was detected in a fraction (7–13%) of
he cells from all three tissue samples tested (Fig. 2A).
ositive cells were detected by EBNA-positive sera only
nd not by EBNA-negative sera. By two-color immuno-
luorescence for simultaneous detection of EBNA and
ytokeratin, EBNA-positive cells were also positive for
ytokeratin (Fig. 2B). They distributed diffusely and did
ot proliferate in discrete foci. LMP1, and the antigens
ssociating with virus replication such as BZLF1 and
p350/220, were not detected. These results suggest
hat EBV-infected carcinoma cells are in a latent state of
BV infection.
etection of EBER1 by ISH
EBER1 was not detected in any of the three tumor
issue samples (Fig. 3A). Conversely, very intense sig-
als were obtained in the EBV-positive gastric carcinoma
issues used as a positive control (Fig. 3B).
To ensure that the EBER1 negativity was transcrip-
ional silencing and not deletion, we checked detectabil-
ty of the EBER DNA sequences by Southern blotting. As
hown in Fig. 4, all three HCC samples were positive for
BER DNA.
etermination of EBV latent gene expression by
estern blotting and RT-PCR
Western blot analysis (Fig. 5) showed that the three
iver tissue samples were positive for EBNA1 but nega-
ive for EBNA2, -3A, -3B, -3C, and -Lp; LMP1; and BZLF1.
T-PCR analysis (Fig. 6) detected Qp- but not Wp- or
p-initiated EBNA mRNA. These results indicate that
BV-infected cells in HCC use the BamHI Q promoter to
ranscribe the EBNA1 gene. RT-PCR analysis showed
TABLE 1
Patient Profile
Case Age/Sex HCVAba HBsAgb
Pathological findings
(N/Tc)
12 49/M 1 2 Mild fibrosis/moderated
21 52/M 1 2 Mild fibrosis/moderate
30 63/M 2 2 Liver cirrhosis/moderate
a Hepatitis C virus antibody.
b Hepatitis B virus surface antigen.
c Nontumorous area/tumorous area.
d Moderately differentiated carcinoma.
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199EBV LATENCY IN HEPATOCELLULAR CARCINOMAhat the BamHI A transcripts were expressed, but LMP1,
2A, and -2B; BZLF1; or EBER1 could not be detected.
onoclonality of EBV-infected cells in HCC
Southern blot hybridization of BamHI-digested DNA
rom each EBV-positive patient (patients 12, 21, and 30)
FIG. 4. Detection of EBER DNA sequences by Southern blotting. The
robe DNA is the 1.0-kb SacI–EcoRI fragment from the EcoRI K frag-
ent of EBV DNA containing the EBER DNA sequences. P, 80 ng of Raji
ell DNA. The number on each lane indicates the patient from whom
he DNA was extracted. l-DNA digested with HindIII was used as a
ize marker and is indicated on the left (in kb pairs).
FIG. 5. EBV-related protein detection by Western blotting with human
erum containing EBNA1, -2, and -3 (A), monoclonal antibodies to
BNA2 and LMP1 (B), EBNA Lp (C), and BZLF1 (D). P1, B lymphoblas-
oid cell lines immortalized by Akata EBV; P2, EBV-positive Akata cells;
1, EBV-negative Akata cells; P3, Akata cells in which virus replication
as induced by cross-linking of surface immunoglobulin G; N2, Akata
ells not treated with surface immunoglobulin G. The number on each
ane indicates the patient from whom the tumor tissue was obtained. ietected a single terminal fragment band between 9.0
nd 14 kb but not a ladder of smaller bands (,6.0 kb)
epresenting the linear EBV genome (Fig. 7). Rehybrid-
zation of the same blots with the EcoRI-I probe again
ielded a single band identical to that detected with the
hoI-a probe (data not shown), suggesting that each
BV-positive case contained EBV DNA in a plasmid form.
DISCUSSION
In the present study, we demonstrated that there is a
igh load of EBV in the liver tissues of patients with HCC.
revious estimates of EBV, based on quantitative analy-
es of DNA content by PCR, indicated that most EBV-
eropositive healthy individuals have less than one copy
FIG. 6. Detection of EBV-related gene expression (A) and the pro-
oter use for EBNA expression (B) and b-actin (C) by RT-PCR and
outhern hybridization. P, PCR products of RNAs extracted from EBV-
ositive Akata cells (for detection of Qp) or lymphoblastoid cells (for
etection of all the transcripts other than Qp). The number on each lane
ndicates the patient number.
FIG. 7. Clonotypic EBV DNA analysis in HCC with the XhoI-a as a
robe. P1, 200 ng of B95–8 cell DNA; P2, 200 ng of Raji cell DNA. The
umber on each lane indicates the patient from whom the DNA was
xtracted. l-DNA digested with HindIII was used as a size marker ands indicated on the left (in kb pairs).
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200 SUGAWARA ET AL.f EBV/105 peripheral blood mononuclear cells (Saito et
l., 1989; Wagner et al., 1992). The present estimate by
outhern blotting indicates that samples from HCC tis-
ues contain .1000 times this level of EBV DNA. We
sed the large internal repeats as hybridization target,
nd Raji cell DNA that we used as a standard for esti-
ation of EBV copy number contained seven repeats.
ecause the number of 3.1-kb repeat units varies con-
iderably among naturally occurring isolates around a
ean of six repeats (Allan et al., 1989), there may be
ome variation in the number of EBV copies estimated in
his assay.
Southern blot hybridization with the XhoI-a as a probe
emonstrated that EBV-positive cells in tumor tissues
rom HCC were monoclonal in origin and were derived
rom a single EBV-infected cell, as in the case of Burkitt’s
ymphoma, nasopharyngeal carcinoma, and gastric car-
inoma (Imai et al., 1994; Rickinson and Kieff, 1996).
owever, the immunofluorescence study indicated that
nly a fraction of the carcinoma cells were infected with
BV. This is in contrast to other EBV-associated malig-
ancies in which all carcinoma cells were infected with
BV. This difference could be due to one of two reasons.
irst, HCC cells were originally 100% EBV positive, but
uring proliferation of HCC, some of them lost the EBV
enome. Alternatively, EBV infection could have occurred
fter carcinogenesis. The diffuse distribution and mono-
lonal nature of the EBV-positive cells suggest that the
ormer hypothesis is more likely.
The growth-promoting properties of EBV are known
ell. It is also possible that EBV-positive HCC cells
romote the proliferation of EBV-negative HCC cells
hrough the secretion of as-yet-unrecognized growth fac-
ors. Moreover, EBV-infected cells are targets of EBV-
pecific cytotoxic T cells (Rickinson and Kieff, 1996).
hus EBV infection could contribute directly to tumori-
enic potential, or it could contribute to HCC by exacer-
ating the inflammatory process in liver tissue. When
onsidering the role of EBV in hepatocarcinogenesis, it is
oteworthy that about 40% of HCV-positive patients had
high EBV load in tumor tissues. Patients 32 and 34 are
lso interesting because they are not infected with HBV
r HCV, and the causative event leading to hepatocarci-
ogenesis is not clear. EBV might be particularly impor-
ant in the development of HCV-related HCC and hepa-
itis virus-negative HCC. However, this study does not
rovide a direct evidence for a causal role of EBV in
epatocarcinogenesis. Further study should clarify the
ignificance of EBV existence in a small fraction of car-
inoma cells.
The most interesting and unique finding is a novel
attern of latent gene expression in HCC tissues. West-
rn blot and RT-PCR analyses indicated that EBV expres-
ion in HCC could be characterized as EBNA1 restricted
Kerr et al., 1992), which is similar to those in Burkitt’s
ymphoma (Rowe et al., 1987) and gastric carcinoma sImai et al., 1994), except for the absence of EBER. RNA
SH showed that EBER was not expressed in EBV-posi-
ive HCC tissues under the condition where intense
ignals were detected in tissues from EBV-positive gas-
ric carcinoma. RT-PCR analysis also failed to detect
BER expression in these tissues, although amplification
f b-actin secured the intact RNA in each HCC speci-
en. These results indicate that EBER RNA is not ex-
ressed in EBV-infected HCC tissues, which implies that
he present gene expression pattern is a novel one. The
mportance of this finding is that the EBER has been
ccepted as a marker of latent EBV infection (Chang et
l., 1992) and as such is routinely used as a diagnostic
ool to detect EBV within tissue samples. The data pre-
ented here suggest that by using the EBER ISH, a
umber of EBV-infected cells could remain undetected.
MATERIALS AND METHODS
atients and tissue specimens
The HCC tumor tissue samples and adjacent nontu-
orous liver tissues were obtained by surgical resection
rom 35 patients who underwent hepatectomy in the
econd Department of Surgery, Tokyo University Hospi-
al, between December 1996 and June 1997. The speci-
ens were each divided into two portions: one was fixed
n 10% formalin and then embedded in paraffin, and the
ther was frozen rapidly and stored at 280°C until use.
The patient population consisted of 25 men and 10
omen, ranging in age from 42 to 73 years (average,
0.9). Pathologically, the nontumorous area included
hronic active hepatitis in 3 patients, fibrosis in 25 pa-
ients, and cirrhosis in 7 patients. The tumor tissues
onsisted of well differentiated HCC in 6 patients, mod-
rately differentiated HCC in 24 patients, poorly differen-
iated HCC in 4 patients, and undifferentiated HCC in 1
atient. Twenty-two patients were HCV antibody positive,
were HBV surface antigen positive, 1 was positive to
oth, and 4 were negative to both. The disease stage
as classified as I in 8 patients, II in 15 patients, and III
n 12 patients according to the staging system of the
merican Joint Committee on Cancer/International Union
gainst Cancer. Normal liver tissues from 35 metastatic
iver carcinomas served as controls.
outhern blot hybridization
High-molecular-mass DNA (20 mg) was extracted from
ach of the frozen tissue specimens, digested with
amHI, separated in a 0.8% agarose gel, and transferred
o a nylon membrane (Hybond N1; Amersham, Arlington
eights, IL). Serially diluted DNA from Raji cells (50
opies of EBV DNA/cell) was used for quantitative esti-
ation of positive bands. The probe DNA was the BamHI
fragment of EBV DNA. For detection of the EBER DNAequences, the cellular DNA was digested with EcoRI
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201EBV LATENCY IN HEPATOCELLULAR CARCINOMAndonuclease, and the 1.0-kb SacI–EcoRI fragment from
he EcoRI K fragment of EBV DNA was used as a probe.
hey were labeled with [32P]dCTP (3000 Ci/mmol) by the
andom primer-based method (Multiprime DNA labeling
ystem; Amersham) according to the manufacturer’s in-
tructions. After hybridization, the membrane was
ashed and exposed to x-ray film.
NA ISH
Sections (5 mm) were cut from the formalin-fixed, par-
ffin-embedded tissue specimens and used for RNA ISH.
BER1 was detected with a digoxigenin-labeled oligonu-
leotide probe complementary to the EBER1 sequence,
9-AGACACCGTCCTCACCACCCGGGACTTGTA-39, using
he procedure described by Chang et al. (1992). A sense
robe for EBER1 was used as a negative control. EBV-
ositive gastric carcinoma tissue samples were used to
repare positive control sections.
rotein expression
The expression of EBNAs 1, -2, -3A, -3B, -3C, and -Lp;
MP1; and BZLF1 was examined by Western blotting
Imai et al., 1998), with reference human serum contain-
ng antibodies to EBNAs and monoclonal antibodies to
BNA2 (PE2), EBNA Lp (JF186), LMP1 (CS1–4), and
ZLF1 (BZ1). The expression of EBNAs, LMP1, BZLF1,
nd gp350/220 was also assessed by immunofluores-
ence as described previously (Imai et al., 1998). Cyto-
eratin was stained by a mixture of type I and II keratin
onoclonal antibodies (AE1 and AE3; ICN ImmunoBio-
ogicals).
everse transcription-polymerase chain reaction
Details of these procedures have been described pre-
iously (Sugiura et al., 1996). Briefly, total RNA was ex-
racted from the frozen tissues using Trizol reagent
GIBCO BRL, Gaithersburg, MD), and the cDNA was
ynthesized from 1 mg of RNA using 10 pmol of each 39
rimer for BamHI-C, -W, and -Q promoters (Cp, Wp, and
p, respectively); LMP1,-2A, and -2B; BZLF1; BamHI-A
ranscripts; and EBER1 (Sugiura et al., 1996; Tierney et
l., 1994). The cDNA synthesized from 100 ng of total
NA was directly subjected to 40 cycles of PCR amplifi-
ation, electrophoresed, blotted onto nylon membranes,
nd hybridized with [32P]ATP-59-end-labeled internal oli-
onucleotide probes. Each reverse transcription-poly-
erase chain reaction (RT-PCR) assay used RNA equiv-
lent to 5000 cells and could detect a single EBV-in-
ected cell for LMP1, -2A, and -2B; BARF0; Cp-initiated
BNA1 mRNAs; and 10 cells for BZLF1-, Wp-, and Qp-
nitiated EBNA1 mRNAs (Sugiura et al., 1996). On the
asis that Raji cells contain 107 copies of EBER/cell
which was the maximum estimate of EBER copies in
BV-infected cells) (Howe et al., 1989), our RT-PCR sys-em could detect 10 copies of EBER in a reaction. The Ouality of the RNA was checked by 30 cycles of amplifi-
ation of cytoplasmic b-actin.
ell clonality
The three samples were examined by Southern blot
ybridization with the 1.9-kb XhoI-a probe from the right-
nd BamHI–Nhet fragment of EBV DNA. Assessment of
ell clonality was performed by counting the number of
used terminal fragment bands of .8.0 kb, which repre-
ent latent infection (Raab-Traub et al., 1986). Hybridiza-
ion with the EcoRI-I probe from the left end of the
enome was also carried out to investigate EBV integra-
ion into the cellular DNA, a rare event reported to occur
t the termini (Matsuo et al., 1984). Blots of BamHI-
igested DNA were first hybridized with the XhoI-a probe
nd then rehybridized with the EcoRI-I probe.
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